Rejected: DFPI's True Lender Claim Against OppFi
LA Superior Court handed OppFi a clean win over DFPI's true lender attack on its FinWise Bank partnership, but DFPI has 60 days to appeal.
LA Superior Court handed OppFi a clean win over DFPI's true lender attack on its FinWise Bank partnership, but DFPI has 60 days to appeal.
Gilead's $3.15B Tubulis bet just got its first public data read: TUB-040 hit 61% response where standard care manages five months.
The CFTC filed first and Kalshi filed second, and Minnesota is now fighting two federal preemption suits before its Aug. 1 felony ban takes effect.
Privacy Enhancing Technologies just cut a 12-month data-transfer wait to two months. The compliance and engineering math now favors founders.
Incyte's phase 3 frontMIND data cuts DLBCL progression risk 25%, but seven drugs and a pending OS read leave the first-line market wide open.
Talapro-3's 52% rPFS reduction spans both BRCA and non-BRCA HRR alterations, the full-spectrum breadth J&J's Akeega couldn't earn from FDA.
Ivonescimab's HARMONi-6 OS data hits ASCO's plenary Sunday, with AbbVie, BioNTech, and Merck holding competing bets on who wins the PD-1/VEGF race.
FDA's second warning to Alchymars in eight years cites the same deteriorated equipment FDA cleared in 2023, plus an import alert on top.
A $10M multistate settlement covers $6.5M in victim restitution, but GreenSky won't admit liability, pinning the scheme on 'prior ownership'.
California's AG named a coding error in DNA Relatives, a five-month detection gap, and misleading public statements as the three pillars of the suit.
Charter turned down ShinyHunters' ransom on 42 million Salesforce records, and the gang posted 4.9 million customer accounts on the dark web.
Anthropic's Series H puts its valuation at $965 billion, a 154% step-up from February, with an investor list that reads like an IPO roadshow roster.
Illinois SB 315 mandates annual third-party audits for frontier AI labs, and OpenAI's own endorsement reveals who the rules are designed to favor.
Pfizer's $650M entry into China's early oncology machine mirrors BMS-Hengrui by two weeks, and neither buyer has Phase 1 data to show for it.
A Michigan drug maker let AI write its specs and skipped validation. The FDA just made it the first cGMP enforcement case naming AI misuse.